Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
Gulsen OzenSofia PedroRebecca SchumacherTeresa A SimonKaleb D MichaudPublished in: Arthritis research & therapy (2019)
In this analysis, abatacept was well tolerated and did not result in an overall increased risk of malignancies, infections or autoimmune diseases compared with other bDMARDs or csDMARDs.